Repositorio Dspace

Long-Term Remission With Low-Dose Rituximab in Myasthenia Gravis: A Retrospective Study

Mostrar el registro sencillo del ítem

dc.contributor.author Castiglione, Juan Ignacio
dc.contributor.author Rivero, Alberto Daniel
dc.contributor.author Barroso, Fabio Adrián
dc.contributor.author Brand, Patricio
dc.contributor.author Lautre, Andrea Rosana
dc.contributor.author Kohler, Alejandro Alfredo
dc.date.accessioned 2022-08-31T17:31:37Z
dc.date.available 2022-08-31T17:31:37Z
dc.date.issued 2022-08-31
dc.identifier.citation Castiglione JI, Rivero AD, Barroso F, Brand P, Lautre AR, Kohler AA. Long-Term Remission With Low-Dose Rituximab in Myasthenia Gravis: A Retrospective Study. J Clin Neuromuscul Dis. 2022 Sep 1;24(1):18-25. doi: 10.1097/CND.0000000000000420. es_ES
dc.identifier.issn 1537-1611
dc.identifier.uri https://repositorio.fleni.org.ar/xmlui/handle/123456789/663
dc.identifier.uri https://doi.org/10.1097/cnd.0000000000000420
dc.description.abstract Objetive: Rituximab (RTX) is a therapeutic option, for patients with myasthenia gravis (MG) not responding to conventional immunosuppressive treatment. In this cohort, we evaluated long-term efficacy of RTX in the treatment of refractory generalized MG. Methods: A retrospective study was performed in adult patients with refractory generalized MG and at least 24 months of follow-up, between January/2015 and October/2021. The Myasthenia Gravis Status and Treatment Intensity Score was used to assess outcomes, and CD19/CD20+ B-cell counts were monitored. Results: Sixteen patients with MG (8 antiacetylcholine receptor+ and 8 muscle-specific antikinase+; mean age 45.5 ± 16.2 years) treated with low-dose RTX protocols were included. CD19/CD20 levels remained undetectable 12 months after induction, and no new relapses were observed during follow-up. Conclusions: Low-dose RTX infusions were sufficient to achieve undetectable CD19/20 cell counts and sustained clinical remission. In low and middle-income countries, the impact of low-dose RTX therapy represents a paradigm shift in decision-making for long-term treatment. es_ES
dc.language.iso eng es_ES
dc.publisher Wolters Kluwer Health es_ES
dc.rights info:eu-repo/semantics/openAccess
dc.rights.uri https://creativecommons.org/licenses/by/2.5/ar/
dc.subject Neoplasm Recurrence, Local / drug therapy es_ES
dc.subject Retrospective Studies es_ES
dc.subject Myasthenia Gravis / drug therapy es_ES
dc.subject Miastenia Gravis /tratamiento farmacológico es_ES
dc.subject Estudios retrospectivos es_ES
dc.subject Recurrencia Local de Neoplasia / tratamiento farmacológico es_ES
dc.title Long-Term Remission With Low-Dose Rituximab in Myasthenia Gravis: A Retrospective Study es_ES
dc.type info:eu-repo/semantics/article es_ES
dc.type info:eu-repo/semantics/publishedVersion
dc.description.fil Fil: Castiglione, Juan Ignacio. Fleni. Departamento de Neurología; Argentina.
dc.description.fil Fil: Rivero, Alberto Daniel. Fleni. Departamento de Neurología; Argentina.
dc.description.fil Fil: Barroso, Fabio Adrián. Fleni. Departamento de Neurología; Argentina.
dc.description.fil Fil: Brand, Patricio. Fleni. Departamento de Neurología; Argentina.
dc.description.fil Fil: Lautre, Andrea Rosana. Fleni. Departamento de Neurología; Argentina.
dc.description.fil Fil: Kohler, Alejandro Alfredo. Fleni. Departamento de Neurología; Argentina.
dc.relation.ispartofVOLUME 24
dc.relation.ispartofNUMBER 1
dc.relation.ispartofPAGINATION 18-25
dc.relation.ispartofCOUNTRY Estados Unidos
dc.relation.ispartofCITY Hagerstown, MD
dc.relation.ispartofTITLE J Clin Neuromuscul Dis
dc.relation.ispartofISSN 1537-1611
dc.type.snrd info:ar-repo/semantics/artículo es_ES


Ficheros en el ítem

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem

info:eu-repo/semantics/openAccess Excepto si se señala otra cosa, la licencia del ítem se describe como info:eu-repo/semantics/openAccess

Buscar en DSpace


Listar

Mi cuenta

Estadísticas